Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
NF-κB degrader 1
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "NF-κB degrader 1" in MCE Product Catalog:
162
162 Cited Publications
Target:
Research Areas:
JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation .
1
1 Cited Publications
Cat. No.: HY-174138
Target:
Research Areas:
NF-κB p105 degrader-1 is a non-covalent, selective Molecular glue-like degrader targeting the NF-κB p105 subunit. NF-κB p105 degrader-1 induces proteasome-mediated degradation via the Cullin-RING ligase SCFβTrCP. NF-κB p105 degrader-1 inhibits LPS-induced production of NO and TNF-α. NF-κB p105 degrader-1 can be used in inflammation-related research .
Cat. No.: HY-170669
CAS No.: 3105680-00-7
PROTAC XPO1 degrader-1 is a CRBN-recruiting PROTAC degrader of exportin 1 (XPO1), with a DC50 of 23.67 nM. It exerts anti-proliferative effects against acute myeloid leukemia cells by inducing XPO1 protein degradation, inhibiting NF-κB activity, inducing apoptosis, and causing G1 cell cycle arrest. PROTAC XPO1 degrader-1 can be used for research on acute myeloid leukemia .
Cat. No.: HY-13982R
CAS No.: 749886-87-1
Target:
Research Areas:
JSH-23 (Standard) is the analytical standard of JSH-23. This product is intended for research and analytical applications. JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation .
Cat. No.: HY-184470
Target:
Research Areas:
MyD88 degrader-1 is an orally active molecular glue degrader targeting MyD88, with a DC50 of 0.74 μM, and exhibits potent anti-inflammatory activity. MyD88 degrader-1 promotes ubiquitination and proteasomal degradation of MyD88, blocks the activation of the NF-κB signaling pathway, and downregulates the transcription of pro-inflammatory genes such as IL-6 and IL-1β. MyD88 degrader-1 alleviates symptoms in acute lung injury models. MyD88 degrader-1 can be used in studies related to acute lung injury .
Cat. No.: HY-187214
Research Areas:
PROTAC G9a degrader-1 is a selective and orally active G9a PROTAC degrader with a DC50 of 1.29 μM. PROTAC G9a degrader-1 inhibits the NF-κB signaling pathway, suppresses the proliferation and migration of cancer cells, promotes apoptosis and cell cycle arrest, and reduces the expression level of H3K9me2. In in vivo models, PROTAC G9a degrader-1 alleviates skin inflammation, reduces epidermal hyperplasia, and decreases Ki67 expression. PROTAC G9a degrader-1 can be used for the research of triple-negative breast cancer and psoriasis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
